Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00295633 · ClinicalTrials.gov registry record · Phase 3
A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 565
- Enrollment target
NCT00295633 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 565 participants.
The verdict
NCT00295633, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 565 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn whether Saxagliptin added to thiazolidinedione (TZD) therapy is more effective than TZD alone as a treatment for Type 2 diabetic subjects who are not sufficiently controlled with TZD alone
Interventions
- DRUG Placebo
- DRUG Saxagliptin
- DRUG pioglitazone
- DRUG rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 565 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00295633
The ClinicalTrials.gov registry entry for NCT00295633 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 565 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00295633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00295633 about?
NCT00295633 is a clinical study titled "A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone". The purpose of this clinical research study is to learn whether Saxagliptin added to thiazolidinedione (TZD) therapy is more effective than TZD alone as a treatment for Type 2 diabetic subjects who are not sufficiently controlled with TZD alone
What is the current status of trial NCT00295633?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 565 participants. The study started on 2006-03. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00295633?
The interventions under investigation include: Placebo (DRUG), Saxagliptin (DRUG), pioglitazone (DRUG), rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00295633?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.